Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030145 | 0.90 | LMNA (0.53) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL28374506 | 0.87 | TSHR (0.55) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL1561685 | 0.86 | CYP3A4 (0.56) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL3339215 | 0.85 | CYP3A4 (0.59) | CYP3A4LMNAACHETSHRSMN1; SMN2 | |
| SCHEMBL31525960 | 0.85 | CYP3A4 (0.59) | CYP3A4LMNAACHETSHRSMN1; SMN2 | |
| SCHEMBL9362791 | 0.85 | CYP3A4 (0.59) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL28374505 | 0.85 | TSHR (0.53) | ACHETSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5540850 | 0.84 | CYP3A4 (0.58) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL6668922 | 0.84 | CYP3A4 (0.62) | CYP3A4LMNACYP4F2CYP4A11ACHE | |
| SCHEMBL2913612 | 0.84 | CYP3A4 (0.58) | CYP3A4LMNACYP4F2CYP4A11ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0497740-B1 | Benzyloxyphenyl derivatives | SANDOZ LTD (CH) | 1994-12-14 | — | — | EP | claimed |
| EP-0497740-A1 | Benzyloxyphenyl derivatives | SANDOZ LTD. (CH) | 1992-08-05 | — | — | EP | claimed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| CN-101404989-A | Antibacterial agent | PROLYSIS LTD (GB) | 2009-04-08 | — | — | CN | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-0579129-B1 | Thiadiazole derivatives for the treatment of depressive states | CT LAB FARM SRL (IT) | 1997-03-05 | — | — | EP | disclosed |
| US-5401853-A | Thiadiazole derivatives for the treatment of depressive states | LABORATORIO FARMACEUTICO C.T. S.R.L. (IT) | 1995-03-28 | — | — | US | disclosed |
| EP-0497740-B1 | Benzyloxyphenyl derivatives | SANDOZ LTD (CH) | 1994-12-14 | — | — | EP | disclosed |
| EP-0579129-A2 | Thiadiazole derivatives for the treatment of depressive states | LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) | 1994-01-19 | — | — | EP | disclosed |
| EP-0497740-A1 | Benzyloxyphenyl derivatives | SANDOZ LTD. (CH) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | CYP3A4 1727/4885LMNA 1041/4885CYP4F2 2415/4885 |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | CYP3A4 1727/4885LMNA 1041/4885CYP4F2 2415/4885 |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | CYP3A4 1727/4885LMNA 1041/4885CYP4F2 2415/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | CYP3A4 795/4885LMNA 1817/4885CYP4F2 1153/4885 |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | CYP3A4 1727/4885LMNA 1041/4885CYP4F2 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.